(4S)-4-(4-fluorophenyl)-1-methyl-2-oxo-3,4-dihydropyridine-5-carboxylic acid | 1263474-42-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (4S)-4-(4-fluorophenyl)-1-methyl-2-oxo-3,4-dihydropyridine-5-carboxylic acid
• 英文别名: (6S)-6-(4-fluorophenyl)-3-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylic Acid；(S)-4-(4-fluoro-phenyl)-1-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid
• CAS: 1263474-42-5
• 化学式: C₁₂H₁₁FN₂O₃
• 分子量: 250.229
• InChiKey: OGRZMSDRNRPVSP-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4S)-4-(4-fluorophenyl)-1-methyl-2-oxo-3,4-dihydropyridine-5-carboxylic acid 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 19.5h， 生成 (6S)-6-(4-fluorophenyl)-3-methyl-N-[2-methyl-5-(2-oxo-1-pyridyl)phenyl]-2-oxo-1,6-dihydropyrimidine-5-carboxamide
  参考文献：
  名称：

  Novel Series of Dihydropyridinone P2X7 Receptor Antagonists

  摘要：

  Identification of singleton P2X7 inhibitor 1 from HTS gave a pharmacophore that eventually turned into potential clinical candidates 17 and 19. During development, a number of issues were successfully addressed, such as metabolic stability, plasma stability, GSH adduct formation, and aniline mutagenicity. Thus, careful modification of the molecule, such as conversion of the 1,4-dihydropyridinone to the 1,2-dihydropyridinone system, proper substitution at C-5", and in some cases addition of fluorine atoms to the aniline ring allowed for the identification of a novel class of potent P2X7 inhibitors suitable for evaluating the role of P2X7 in inflammatory, immune, neurologic, or musculoskeletal disorders.

  DOI：

  10.1021/acs.jmedchem.5b00365
• 作为产物：
  描述：

  ethyl 6-(4-fluorophenyl)-3-methyl-2-oxo-1,6-dihydropyrimidine-5-carboxylate ester 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 1.0h， 生成 (4S)-4-(4-fluorophenyl)-1-methyl-2-oxo-3,4-dihydropyridine-5-carboxylic acid
  参考文献：
  名称：

  Novel Series of Dihydropyridinone P2X7 Receptor Antagonists

  摘要：

  Identification of singleton P2X7 inhibitor 1 from HTS gave a pharmacophore that eventually turned into potential clinical candidates 17 and 19. During development, a number of issues were successfully addressed, such as metabolic stability, plasma stability, GSH adduct formation, and aniline mutagenicity. Thus, careful modification of the molecule, such as conversion of the 1,4-dihydropyridinone to the 1,2-dihydropyridinone system, proper substitution at C-5", and in some cases addition of fluorine atoms to the aniline ring allowed for the identification of a novel class of potent P2X7 inhibitors suitable for evaluating the role of P2X7 in inflammatory, immune, neurologic, or musculoskeletal disorders.

  DOI：

  10.1021/acs.jmedchem.5b00365

文献信息

• DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS
  申请人：Brotherton-Pleiss Christine E.

  公开号：US20110028502A1

  公开（公告）日：2011-02-03

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R a and R b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  化合物的公式I：或其药用盐，其中m、n、R1、R2、R3、R4、R5、Ra和Rb的定义如本文所述。还公开了制备这些化合物的方法以及利用这些化合物治疗与P2X7嘌呤受体相关的疾病的方法。
• Dihydropyrimidone amides as P2X7 modulators
  申请人：Brotherton-Pleiss Christine E.

  公开号：US08435990B2

  公开（公告）日：2013-05-07

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5, Ra and Rb are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  公式I的化合物或其药学上可接受的盐，其中m、n、R1、R2、R3、R4、R5、Ra和Rb的定义如本文所述。还披露了制备这些化合物的方法，并使用这些化合物治疗与P2X7嘌呤能受体相关的疾病。
• US8435990B2
  申请人：——

  公开号：US8435990B2

  公开（公告）日：2013-05-07
• [EN] DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS<br/>[FR] AMIDES DE DIHYDROPYRIMIDONE UTILISÉS COMME MODULATEURS P2X7
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011012592A1

  公开（公告）日：2011-02-03

  Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4, R5, Ra and Rb are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.